UroGen Pharma Ltd. Current Federal Tax Expense (Benefit)
UroGen Pharma Ltd. (URGN) reported Current Federal Tax Expense (Benefit) of $196.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Expense Statement › Income Tax
us-gaap:CurrentFederalTaxExpenseBenefit · last filed 2026-03-02
- UroGen Pharma Ltd. current federal tax expense (benefit) for fiscal 2025 was $196.00K, a 91.12% decline from fiscal 2024.
- UroGen Pharma Ltd. current federal tax expense (benefit) for fiscal 2024 was $2.21M, a 24.89% decline from fiscal 2023.
- UroGen Pharma Ltd. current federal tax expense (benefit) for fiscal 2023 was $2.94M, a 402.91% increase from fiscal 2022.
- UroGen Pharma Ltd. current federal tax expense (benefit) for fiscal 2022 was $584.00K, a 59.83% decline from fiscal 2021.
| Period end | Current Federal Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | $196.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | $2.21M 10-K · filed 2026-03-02 |
| 2023-12-31 | $2.94M 10-K · filed 2025-03-10 |
| 2022-12-31 | $584.00K 10-K · filed 2024-03-14 |
| 2021-12-31 | $1.45M 10-K · filed 2023-03-24 |
| 2020-12-31 | $3.22M 10-K · filed 2022-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B |